PMC:7105881 / 32722-33152 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1037","span":{"begin":83,"end":87},"obj":"Gene"},{"id":"1045","span":{"begin":121,"end":126},"obj":"Species"},{"id":"1046","span":{"begin":191,"end":199},"obj":"Species"},{"id":"1047","span":{"begin":289,"end":297},"obj":"Species"},{"id":"1050","span":{"begin":140,"end":153},"obj":"Disease"},{"id":"1051","span":{"begin":165,"end":173},"obj":"Disease"},{"id":"1052","span":{"begin":255,"end":263},"obj":"Disease"},{"id":"1053","span":{"begin":270,"end":278},"obj":"Disease"},{"id":"1055","span":{"begin":234,"end":240},"obj":"CellLine"}],"attributes":[{"id":"A1037","pred":"tao:has_database_id","subj":"1037","obj":"Gene:59272"},{"id":"A1045","pred":"tao:has_database_id","subj":"1045","obj":"Tax:9606"},{"id":"A1046","pred":"tao:has_database_id","subj":"1046","obj":"Tax:694009"},{"id":"A1047","pred":"tao:has_database_id","subj":"1047","obj":"Tax:694009"},{"id":"A1050","pred":"tao:has_database_id","subj":"1050","obj":"MESH:D054198"},{"id":"A1051","pred":"tao:has_database_id","subj":"1051","obj":"MESH:D007239"},{"id":"A1052","pred":"tao:has_database_id","subj":"1052","obj":"MESH:D008223"},{"id":"A1053","pred":"tao:has_database_id","subj":"1053","obj":"MESH:D007239"},{"id":"A1055","pred":"tao:has_database_id","subj":"1055","obj":"CVCL:0511"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Nevertheless, this vaccine also resulted in Fcγ receptor II (FcγRII)-dependent and ACE2-independent ADE, particularly in human monocytic or lymphoblastic cell lines infected with pseudotyped SARS-CoV expressing viral S protein, or in Raji B cells (B-cell lymphoma line) infected with live SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising significant concerns over the use of full-length S protein as a SARS vaccine target."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T181","span":{"begin":127,"end":136},"obj":"Body_part"},{"id":"T182","span":{"begin":140,"end":153},"obj":"Body_part"},{"id":"T183","span":{"begin":154,"end":158},"obj":"Body_part"},{"id":"T184","span":{"begin":219,"end":226},"obj":"Body_part"},{"id":"T185","span":{"begin":241,"end":246},"obj":"Body_part"},{"id":"T186","span":{"begin":250,"end":254},"obj":"Body_part"},{"id":"T187","span":{"begin":397,"end":404},"obj":"Body_part"}],"attributes":[{"id":"A181","pred":"fma_id","subj":"T181","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A182","pred":"fma_id","subj":"T182","obj":"http://purl.org/sig/ont/fma/fma83030"},{"id":"A183","pred":"fma_id","subj":"T183","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A184","pred":"fma_id","subj":"T184","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A185","pred":"fma_id","subj":"T185","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A186","pred":"fma_id","subj":"T186","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A187","pred":"fma_id","subj":"T187","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Nevertheless, this vaccine also resulted in Fcγ receptor II (FcγRII)-dependent and ACE2-independent ADE, particularly in human monocytic or lymphoblastic cell lines infected with pseudotyped SARS-CoV expressing viral S protein, or in Raji B cells (B-cell lymphoma line) infected with live SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising significant concerns over the use of full-length S protein as a SARS vaccine target."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T169","span":{"begin":100,"end":103},"obj":"Disease"},{"id":"T170","span":{"begin":191,"end":199},"obj":"Disease"},{"id":"T171","span":{"begin":248,"end":263},"obj":"Disease"},{"id":"T173","span":{"begin":255,"end":263},"obj":"Disease"},{"id":"T174","span":{"begin":289,"end":297},"obj":"Disease"},{"id":"T175","span":{"begin":410,"end":414},"obj":"Disease"}],"attributes":[{"id":"A169","pred":"mondo_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/MONDO_0019383"},{"id":"A170","pred":"mondo_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A171","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0004095"},{"id":"A172","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0015759"},{"id":"A173","pred":"mondo_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/MONDO_0005062"},{"id":"A174","pred":"mondo_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A175","pred":"mondo_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Nevertheless, this vaccine also resulted in Fcγ receptor II (FcγRII)-dependent and ACE2-independent ADE, particularly in human monocytic or lymphoblastic cell lines infected with pseudotyped SARS-CoV expressing viral S protein, or in Raji B cells (B-cell lymphoma line) infected with live SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising significant concerns over the use of full-length S protein as a SARS vaccine target."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T430","span":{"begin":44,"end":46},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T431","span":{"begin":61,"end":63},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T432","span":{"begin":121,"end":126},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T433","span":{"begin":127,"end":136},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T434","span":{"begin":154,"end":164},"obj":"http://purl.obolibrary.org/obo/CLO_0000031"},{"id":"T435","span":{"begin":234,"end":238},"obj":"http://purl.obolibrary.org/obo/CLO_0008734"},{"id":"T436","span":{"begin":234,"end":238},"obj":"http://purl.obolibrary.org/obo/CLO_0051728"},{"id":"T437","span":{"begin":239,"end":246},"obj":"http://purl.obolibrary.org/obo/CL_0000236"},{"id":"T438","span":{"begin":248,"end":254},"obj":"http://purl.obolibrary.org/obo/CL_0000236"},{"id":"T439","span":{"begin":408,"end":409},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Nevertheless, this vaccine also resulted in Fcγ receptor II (FcγRII)-dependent and ACE2-independent ADE, particularly in human monocytic or lymphoblastic cell lines infected with pseudotyped SARS-CoV expressing viral S protein, or in Raji B cells (B-cell lymphoma line) infected with live SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising significant concerns over the use of full-length S protein as a SARS vaccine target."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T193","span":{"begin":57,"end":59},"obj":"Chemical"},{"id":"T194","span":{"begin":219,"end":226},"obj":"Chemical"},{"id":"T195","span":{"begin":397,"end":404},"obj":"Chemical"}],"attributes":[{"id":"A193","pred":"chebi_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A194","pred":"chebi_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A195","pred":"chebi_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Nevertheless, this vaccine also resulted in Fcγ receptor II (FcγRII)-dependent and ACE2-independent ADE, particularly in human monocytic or lymphoblastic cell lines infected with pseudotyped SARS-CoV expressing viral S protein, or in Raji B cells (B-cell lymphoma line) infected with live SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising significant concerns over the use of full-length S protein as a SARS vaccine target."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T11","span":{"begin":248,"end":263},"obj":"Phenotype"}],"attributes":[{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0012191"}],"text":"Nevertheless, this vaccine also resulted in Fcγ receptor II (FcγRII)-dependent and ACE2-independent ADE, particularly in human monocytic or lymphoblastic cell lines infected with pseudotyped SARS-CoV expressing viral S protein, or in Raji B cells (B-cell lymphoma line) infected with live SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising significant concerns over the use of full-length S protein as a SARS vaccine target."}

{"project":"2_test","denotations":[{"id":"32265848-17049691-36511134","span":{"begin":311,"end":315},"obj":"17049691"},{"id":"32265848-22311359-36511135","span":{"begin":331,"end":335},"obj":"22311359"}],"text":"Nevertheless, this vaccine also resulted in Fcγ receptor II (FcγRII)-dependent and ACE2-independent ADE, particularly in human monocytic or lymphoblastic cell lines infected with pseudotyped SARS-CoV expressing viral S protein, or in Raji B cells (B-cell lymphoma line) infected with live SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising significant concerns over the use of full-length S protein as a SARS vaccine target."}

{"project":"LitCovid-sentences","denotations":[{"id":"T196","span":{"begin":0,"end":430},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Nevertheless, this vaccine also resulted in Fcγ receptor II (FcγRII)-dependent and ACE2-independent ADE, particularly in human monocytic or lymphoblastic cell lines infected with pseudotyped SARS-CoV expressing viral S protein, or in Raji B cells (B-cell lymphoma line) infected with live SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising significant concerns over the use of full-length S protein as a SARS vaccine target."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T543","span":{"begin":83,"end":87},"obj":"G_3;PG_10;PR:000003622"},{"id":"T544","span":{"begin":121,"end":126},"obj":"SP_6;NCBITaxon:9606"},{"id":"T545","span":{"begin":127,"end":136},"obj":"CL:0000576"},{"id":"T546","span":{"begin":191,"end":199},"obj":"SP_10"},{"id":"T547","span":{"begin":200,"end":210},"obj":"GO:0010467"},{"id":"T548","span":{"begin":211,"end":216},"obj":"NCBITaxon:10239"},{"id":"T549","span":{"begin":217,"end":226},"obj":"PG_1"},{"id":"T550","span":{"begin":239,"end":246},"obj":"CL:0000236"},{"id":"T551","span":{"begin":248,"end":254},"obj":"CL:0000236"},{"id":"T552","span":{"begin":289,"end":297},"obj":"SP_10"},{"id":"T553","span":{"begin":395,"end":404},"obj":"PG_1"},{"id":"T554","span":{"begin":410,"end":414},"obj":"SP_10"},{"id":"T24672","span":{"begin":83,"end":87},"obj":"G_3;PG_10;PR:000003622"},{"id":"T34596","span":{"begin":121,"end":126},"obj":"SP_6;NCBITaxon:9606"},{"id":"T78001","span":{"begin":127,"end":136},"obj":"CL:0000576"},{"id":"T51847","span":{"begin":191,"end":199},"obj":"SP_10"},{"id":"T5780","span":{"begin":200,"end":210},"obj":"GO:0010467"},{"id":"T88105","span":{"begin":211,"end":216},"obj":"NCBITaxon:10239"},{"id":"T44559","span":{"begin":217,"end":226},"obj":"PG_1"},{"id":"T7143","span":{"begin":239,"end":246},"obj":"CL:0000236"},{"id":"T24600","span":{"begin":248,"end":254},"obj":"CL:0000236"},{"id":"T5374","span":{"begin":289,"end":297},"obj":"SP_10"},{"id":"T12423","span":{"begin":395,"end":404},"obj":"PG_1"},{"id":"T58430","span":{"begin":410,"end":414},"obj":"SP_10"}],"text":"Nevertheless, this vaccine also resulted in Fcγ receptor II (FcγRII)-dependent and ACE2-independent ADE, particularly in human monocytic or lymphoblastic cell lines infected with pseudotyped SARS-CoV expressing viral S protein, or in Raji B cells (B-cell lymphoma line) infected with live SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising significant concerns over the use of full-length S protein as a SARS vaccine target."}